CDK 4/6 inhibitors — Competitive Intelligence Brief

CDK 4/6 inhibitors (CDK 4/6 inhibitors) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK 4/6 inhibitor. Area: Oncology.

phase 3 CDK 4/6 inhibitor CDK4, CDK6 Oncology Small molecule

Target snapshot

CDK 4/6 inhibitors (CDK 4/6 inhibitors) — Region Örebro County. CDK 4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression at the G1/S checkpoint.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CDK 4/6 inhibitors TARGET	CDK 4/6 inhibitors	Region Örebro County	phase 3	CDK 4/6 inhibitor	CDK4, CDK6
CDK4/6i	CDK4/6i	Hoffmann-La Roche	phase 3	CDK4/6 inhibitor	CDK4, CDK6
(CDK)4/6 inhibitor	(CDK)4/6 inhibitor	Tianjin Medical University Cancer Institute and Hospital	phase 3	CDK4/6 inhibitor	CDK4, CDK6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK 4/6 inhibitor class)

1. Region Örebro County · 1 drug in this class